Government-Owned Inventions; Availability for Licensing, 25806 [2017-11492]
Download as PDF
25806
Federal Register / Vol. 82, No. 106 / Monday, June 5, 2017 / Notices
Dated: May 30, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–11497 Filed 6–2–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Chris Kornak, J.D., 240–627–3705,
chris.kornak@nih.gov. Licensing
information and copies of the U.S.
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Methods for Treating Cerebral Edema
and Restoring Blood-Brain Barrier
Integrity
Description of Technology: There are
nearly 600 million clinical cases of
Plasmodium falciparum malaria
annually. For most individuals living in
endemic areas, malaria is
uncomplicated and resolves with time.
However, malaria can become severe
and life threatening in young children,
which resulted in 429,000 deaths in
2015. One of the most deadly
complications of P. falciparum infection
is cerebral malaria (HCM) characterized
by the onset of severe neurological signs
such as altered consciousness, seizures,
and coma. Thus, there is an urgent need
for the development of effective
adjunctive therapies that can be used in
VerDate Sep<11>2014
17:31 Jun 02, 2017
Jkt 241001
conjunction with anti-malarials to treat
children with HCM.
The inventors, listed below, have
discovered that glutamine antagonists
can be used to treat mice with
experimental cerebral malaria (ECM) in
conjunction with anti-malarials. It was
found that glutamine antagonist, 6diazo-5-L-norleucine (DON)
successfully restored blood-brain barrier
integrity and decreased brain swelling
in ECM mice. This finding suggests that
glutamine antagonists may be effective
in treating neurological damage in HCM
patients.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Therapeutic for cerebral malaria
Competitive Advantages:
• Effective adjunctive therapeutics for
cerebral malaria are not available.
Development Stage: Pre-Clinical.
Inventors: Susan K. Pierce, NIAID,
NIH, Johnathan Powell, Johns Hopkins
University.
Publications: Gordon, Emile B., et al.
(2015) Targeting glutamine metabolism
rescues mice from late-stage cerebral
malaria. PNAS 112(42): 13075–13080.
Intellectual Property: HHS Reference
No. E–202–2015/0—US Provisional
Patent Application No. 62/175,000 filed
June 12, 2015; PCT Patent Application
No. PCT/US2016/036996 filed June 10,
2016.
Licensing Contact: Chris Kornak, J.D.,
240–627–3705, chris.kornak@nih.gov.
Collaborative Research Opportunity:
For collaboration opportunities, please
contact Chris Kornak, J.D. 240–627–
3705, chris.kornak@nih.gov.
Dated: May 24, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–11492 Filed 6–2–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK Research
Project Grants.
Date: June 20, 2017.
Time: 3:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Elena Sanovich, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7351, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, 301–594–8886,
sanoviche@mail.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Time-Sensitive
Obesity.
Date: June 21, 2017.
Time: 10:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7353, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Preventing Type 2
Diabetes.
Date: June 28, 2017.
Time: 10:00 a.m. to 11:00 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7353, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK PTH
Receptor (P01).
Date: July 25, 2017.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\05JNN1.SGM
05JNN1
Agencies
[Federal Register Volume 82, Number 106 (Monday, June 5, 2017)]
[Notices]
[Page 25806]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-11492]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Chris Kornak, J.D., 240-627-3705,
chris.kornak@nih.gov. Licensing information and copies of the U.S.
patent applications listed below may be obtained by communicating with
the indicated licensing contact at the Technology Transfer and
Intellectual Property Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required
to receive copies of unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Methods for Treating Cerebral Edema and Restoring Blood-Brain Barrier
Integrity
Description of Technology: There are nearly 600 million clinical
cases of Plasmodium falciparum malaria annually. For most individuals
living in endemic areas, malaria is uncomplicated and resolves with
time. However, malaria can become severe and life threatening in young
children, which resulted in 429,000 deaths in 2015. One of the most
deadly complications of P. falciparum infection is cerebral malaria
(HCM) characterized by the onset of severe neurological signs such as
altered consciousness, seizures, and coma. Thus, there is an urgent
need for the development of effective adjunctive therapies that can be
used in conjunction with anti-malarials to treat children with HCM.
The inventors, listed below, have discovered that glutamine
antagonists can be used to treat mice with experimental cerebral
malaria (ECM) in conjunction with anti-malarials. It was found that
glutamine antagonist, 6-diazo-5-L-norleucine (DON) successfully
restored blood-brain barrier integrity and decreased brain swelling in
ECM mice. This finding suggests that glutamine antagonists may be
effective in treating neurological damage in HCM patients.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
Therapeutic for cerebral malaria
Competitive Advantages:
Effective adjunctive therapeutics for cerebral malaria are
not available.
Development Stage: Pre-Clinical.
Inventors: Susan K. Pierce, NIAID, NIH, Johnathan Powell, Johns
Hopkins University.
Publications: Gordon, Emile B., et al. (2015) Targeting glutamine
metabolism rescues mice from late-stage cerebral malaria. PNAS 112(42):
13075-13080.
Intellectual Property: HHS Reference No. E-202-2015/0--US
Provisional Patent Application No. 62/175,000 filed June 12, 2015; PCT
Patent Application No. PCT/US2016/036996 filed June 10, 2016.
Licensing Contact: Chris Kornak, J.D., 240-627-3705,
chris.kornak@nih.gov.
Collaborative Research Opportunity: For collaboration
opportunities, please contact Chris Kornak, J.D. 240-627-3705,
chris.kornak@nih.gov.
Dated: May 24, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-11492 Filed 6-2-17; 8:45 am]
BILLING CODE 4140-01-P